Moderna’s mRNA Flu Vaccine Approved by FDA
The agency requires more data to prove efficacy for over 65s, but has licensed the first mRNA-based flu shot in the United States for those aged 50–64.
TL;DR
- FDA approves Moderna's mFlusiva, the first mRNA vaccine for seasonal flu.
- Approved for adults aged 50-64 (traditional approval) and over-65s (accelerated approval).
- Moderna needs to provide more data on efficacy for the over-65 age group.
- A late-stage trial showed the shot was 26.5% more effective than a standard-dose flu vaccine.